IN BRIEF: RTW Biotech makes additional investment in Windward Bio
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Invests USD1.7 million as part of portfolio company Windward Bio's USD165 million crossover financing. RTW Biotech says it first invested in the private, clinical-stage biotechnology company as part of its series A round back in January of last year. Notes that Windward Bio is focused on improving outcomes for people living with serious immunological diseases, with its lead programme WIN378 an antibody designed to treat asthma and chronic obstructive pulmonary disease. Read More